Ester Pungolino
Overview
Explore the profile of Ester Pungolino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
918
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zambrotta G, Nicolini F, Assouline S, Busque L, Pungolino E, Abruzzese E, et al.
Am J Hematol
. 2023 Aug;
98(11):1762-1771.
PMID: 37647134
Disease progression to accelerated/blast phase (AP/BP) in patients with chronic phase chronic myeloid leukemia (CP-CML) after treatment discontinuation (TD) has never been systematically reported in clinical trials. However, recent reports...
2.
LAbbate A, Moretti V, Pungolino E, Micheloni G, Valli R, Frattini A, et al.
Genes (Basel)
. 2023 Jul;
14(7).
PMID: 37510256
Chronic myeloid leukemia (CML) is a rare myeloproliferative disorder caused by the reciprocal translocation t(9;22)(q34;q11) in hematopoietic stem cells (HSCs). This chromosomal translocation results in the formation of an extra-short...
3.
Guglielmelli P, Kiladjian J, Vannucchi A, Duan M, Meng H, Pan L, et al.
Ther Adv Hematol
. 2022 Sep;
13:20406207221118429.
PMID: 36105914
Background: Thrombocytopenia is a common feature of myelofibrosis (MF), a myeloproliferative neoplasm driven by dysregulated JAK/STAT signaling; however, pivotal trials assessing the efficacy of ruxolitinib (a JAK1/2 inhibitor) excluded MF...
4.
Pungolino E, DAdda M, De Canal G, Trojani A, Perego A, Elena C, et al.
Eur J Haematol
. 2021 Jun;
107(4):436-448.
PMID: 34139044
Chronic Myeloid Leukemia is a clonal disorder characterized by the presence of the Ph-chromosome and the BCR-ABL tyrosine-kinase (TK). Target-therapy with Imatinib has greatly improved its outcome. Deeper and faster...
5.
Houshmand M, Garello F, Stefania R, Gaidano V, Cignetti A, Spinelli M, et al.
Cancers (Basel)
. 2021 Apr;
13(6).
PMID: 33804056
CML is a hematopoietic stem-cell disorder emanating from breakpoint cluster region/Abelson murine leukemia 1 (BCR/ABL) translocation. Introduction of different TKIs revolutionized treatment outcome in CML patients, but CML LSCs seem...
6.
Gemelli M, Elli E, Elena C, Iurlo A, Intermesoli T, Maffioli M, et al.
Blood Res
. 2020 Aug;
55(3):139-145.
PMID: 32792470
Background: Generic formulations of imatinib mesylate have been introduced in Western Europe since 2017 to treat patients with chronic myeloid leukemia (CML). However, results on the safety and efficacy of...
7.
Diral E, Mori S, Antolini L, Abruzzese E, le Coutre P, Martino B, et al.
Blood
. 2020 Jun;
136(19):2237-2240.
PMID: 32518953
No abstract available.
8.
Trojani A, Pungolino E, Dal Molin A, Lodola M, Rossi G, DAdda M, et al.
PLoS One
. 2019 Jul;
14(7):e0218444.
PMID: 31318870
Chronic myeloid leukemia (CML) is characterized by the constitutive tyrosine kinase activity of the oncoprotein BCR-ABL1 in myeloid progenitor cells that activates multiple signal transduction pathways leading to the leukemic...
9.
Abruzzese E, Bosi A, Breccia M, DAdda M, Di Renzo N, Liberati A, et al.
Mediterr J Hematol Infect Dis
. 2019 Jun;
11(1):e2019025.
PMID: 31205629
Background And Objectives: While tyrosine kinase inhibitors (TKIs) have transformed CP-CML management, limited data exist on their use in clinical practice. Methods: SIMPLICITY (NCT01244750) is an observational study in CP-CML...
10.
Pungolino E, Rossi G, De Canal G, Trojani A, DAdda M, Perego A, et al.
Am J Hematol
. 2018 Apr;
93(7):E162-E164.
PMID: 29633310
No abstract available.